drugset / Trial / NCT00003917

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00003917

RandomizedSingle-groupTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth. PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.

Timeline

Start
1999-03
Primary completion
2001-11
Completion
2001-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule 1.5 mg/m2 Intravenous
Subject Topotecan Small molecule 2.3 mg/m2 Intravenous